Apremilast

BNF:: 10.1.3 & 13.5.3
Status:: Red
Decision Date:: May 2015

Comments

RED:

NICE TA419: for treating moderate to severe plaque psoriasis. (Decision date - December 2016).
NICE TA433: for treating active psoriatic arthritis. (Decision date - March 2017).

Red Drug Classifications

1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)